İmmünoterapi

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (yeni pencere açar)

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS

Kaynak‎: N Engl J Med 2017;376(9):836-47.

İndeks‎: PubMed 28249141

DOI‎: 10.1056/NEJMoa1609783

https://www.ncbi.nlm.nih.gov/pubmed/28249141 (yeni pencere açar)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (yeni pencere açar)

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

Kaynak‎: N Engl J Med 2014;371(16):1507-17.

İndeks‎: PubMed 25317870

DOI‎: 10.1056/NEJMoa1407222

https://www.ncbi.nlm.nih.gov/pubmed/25317870 (yeni pencere açar)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (yeni pencere açar)

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA

Kaynak‎: N Engl J Med 2018;378(5):439-48.

İndeks‎: PubMed 29385370

DOI‎: 10.1056/NEJMoa1709866

https://www.ncbi.nlm.nih.gov/pubmed/29385370 (yeni pencere açar)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (yeni pencere açar)

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE

Kaynak‎: Cancer 2013;119(22):4036-43.

İndeks‎: PubMed 24006085

DOI‎: 10.1002/cncr.28334

https://www.ncbi.nlm.nih.gov/pubmed/24006085 (yeni pencere açar)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (yeni pencere açar)

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S

Kaynak‎: Clin Cancer Res 2016;22(8):1951-7.

İndeks‎: PubMed 26644412

DOI‎: 10.1158/1078-0432.CCR-15-1349

https://www.ncbi.nlm.nih.gov/pubmed/26644412 (yeni pencere açar)

ONKOLOJI (ÇOCUK)

İmmünoterapi

Türkçe

İmmünoterapi

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (yeni pencere açar)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (yeni pencere açar)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (yeni pencere açar)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (yeni pencere açar)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (yeni pencere açar)

Hastane İrtibat Heyeti Yerel Temsilcisiyle İletişime Geçin

Tıbbi Bilgilendirme Paketleri

Videolar

İmmünoterapi

Dilinizi Seçin

Paylaş